Stryker Corporation (SYK) Shares Sold by Wheatland Advisors Inc.

Wheatland Advisors Inc. lowered its position in Stryker Corporation (NYSE:SYK) by 10.6% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,409 shares of the medical technology company’s stock after selling 999 shares during the period. Wheatland Advisors Inc.’s holdings in Stryker Corporation were worth $1,107,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Independent Advisor Alliance bought a new position in shares of Stryker Corporation during the fourth quarter worth approximately $107,000. FUKOKU MUTUAL LIFE INSURANCE Co bought a new position in shares of Stryker Corporation during the fourth quarter worth approximately $108,000. Bollard Group LLC raised its position in shares of Stryker Corporation by 0.4% in the first quarter. Bollard Group LLC now owns 829 shares of the medical technology company’s stock worth $109,000 after buying an additional 3 shares in the last quarter. Salem Investment Counselors Inc. bought a new position in shares of Stryker Corporation during the third quarter worth approximately $116,000. Finally, Baystate Wealth Management LLC raised its position in shares of Stryker Corporation by 2.1% in the first quarter. Baystate Wealth Management LLC now owns 1,066 shares of the medical technology company’s stock worth $139,000 after buying an additional 22 shares in the last quarter. 74.28% of the stock is owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Stryker Corporation (NYSE:SYK)

Shares of Stryker Corporation (NYSE:SYK) traded up 0.72% during mid-day trading on Friday, hitting $142.24. 1,583,290 shares of the company traded hands. The stock has a market capitalization of $53.16 billion, a price-to-earnings ratio of 31.96 and a beta of 0.81. Stryker Corporation has a one year low of $106.48 and a one year high of $145.62. The firm has a 50-day moving average of $138.95 and a 200-day moving average of $128.75.

Stryker Corporation (NYSE:SYK) last posted its quarterly earnings data on Tuesday, April 25th. The medical technology company reported $1.48 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.43 by $0.05. Stryker Corporation had a return on equity of 24.26% and a net margin of 14.33%. The firm had revenue of $2.96 billion for the quarter, compared to the consensus estimate of $2.90 billion. During the same quarter in the previous year, the business earned $1.24 EPS. The company’s quarterly revenue was up 18.4% compared to the same quarter last year. On average, equities analysts predict that Stryker Corporation will post $6.43 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, July 31st. Stockholders of record on Friday, June 30th will be given a dividend of $0.425 per share. The ex-dividend date is Wednesday, June 28th. This represents a $1.70 annualized dividend and a dividend yield of 1.20%. Stryker Corporation’s dividend payout ratio is currently 38.20%.

TRADEMARK VIOLATION NOTICE: “Stryker Corporation (SYK) Shares Sold by Wheatland Advisors Inc.” was published by Transcript Daily and is the property of of Transcript Daily. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://transcriptdaily.com/2017/06/17/wheatland-advisors-inc-sells-999-shares-of-stryker-co-syk-updated-updated.html.

Several research analysts recently issued reports on SYK shares. Citigroup Inc. increased their price target on shares of Stryker Corporation from $114.00 to $125.00 and gave the stock a “sell” rating in a research report on Friday, June 9th. Oppenheimer Holdings, Inc. set a $135.00 price objective on shares of Stryker Corporation and gave the stock a “hold” rating in a research note on Saturday, April 8th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $140.00 price objective (up from $135.00) on shares of Stryker Corporation in a research note on Wednesday, April 26th. Deutsche Bank AG reissued a “buy” rating and set a $148.00 price target (up from $135.00) on shares of Stryker Corporation in a research note on Saturday, April 29th. Finally, Piper Jaffray Companies reissued an “overweight” rating and set a $148.00 price target on shares of Stryker Corporation in a research note on Monday, April 17th. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $134.29.

In related news, insider David Floyd sold 7,381 shares of the company’s stock in a transaction dated Monday, June 5th. The stock was sold at an average price of $144.70, for a total value of $1,068,030.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Timothy J. Scannell sold 13,322 shares of the company’s stock in a transaction dated Tuesday, May 2nd. The shares were sold at an average price of $135.89, for a total value of $1,810,326.58. The disclosure for this sale can be found here. Corporate insiders own 7.40% of the company’s stock.

Stryker Corporation Company Profile

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply